Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NYSE:GEN

Genesis Healthcare (GEN) Stock Price, News & Analysis

Genesis Healthcare logo

About Genesis Healthcare Stock (NYSE:GEN)

Key Stats

Today's Range
$27.27
$28.14
50-Day Range
$0.18
$0.60
52-Week Range
$0.40
$1.37
Volume
13.75 million shs
Average Volume
4.10 million shs
Market Capitalization
$17.79 billion
P/E Ratio
30.92
Dividend Yield
1.80%
Price Target
$31.33
Consensus Rating
Moderate Buy

Company Overview

Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services; Rehabilitation Therapy Services; and Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of December 31, 2020, it provided inpatient services through a network of approximately 341 skilled nursing facilities and assisted/senior living communities in 24 states; and supplied rehabilitation and respiratory therapy to approximately 1,400 healthcare locations in 42 states, the District of Columbia and China. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.

Genesis Healthcare Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
37th Percentile Overall Score

GEN MarketRank™: 

Genesis Healthcare scored higher than 37% of companies evaluated by MarketBeat, and ranked 227th out of 333 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Genesis Healthcare has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Genesis Healthcare has only been the subject of 4 research reports in the past 90 days.

  • Read more about Genesis Healthcare's stock forecast and price target.
  • Earnings Growth

    Earnings for Genesis Healthcare are expected to grow by 5.52% in the coming year, from $1.63 to $1.72 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Genesis Healthcare is 30.92, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.35.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Genesis Healthcare is 30.92, which means that it is trading at a more expensive P/E ratio than the Business Services sector average P/E ratio of about 28.40.

  • Short Interest

    There is no current short interest data available for GEN.
  • Dividend Yield

    Genesis Healthcare pays a meaningful dividend of 3.05%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Genesis Healthcare does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Genesis Healthcare is 55.56%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Genesis Healthcare will have a dividend payout ratio of 29.07% next year. This indicates that Genesis Healthcare will be able to sustain or increase its dividend.

  • Read more about Genesis Healthcare's dividend.
  • Short Interest

    There is no current short interest data available for GEN.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Genesis Healthcare this week, compared to 5 articles on an average week.
  • Search Interest

    Only 8 people have searched for GEN on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Genesis Healthcare to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Genesis Healthcare insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,476,708.00 in company stock.

  • Percentage Held by Insiders

    Only 3.30% of the stock of Genesis Healthcare is held by insiders.

  • Percentage Held by Institutions

    82.08% of the stock of Genesis Healthcare is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Genesis Healthcare's insider trading history.
Receive GEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genesis Healthcare and its competitors with MarketBeat's FREE daily newsletter.

GEN Stock News Headlines

The 2 Best Dividend Stocks to Buy Under $30
2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis
Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.
See More Headlines

GEN Stock Analysis - Frequently Asked Questions

Genesis Healthcare, Inc. (NYSE:GEN) announced its quarterly earnings data on Wednesday, October, 30th. The company reported $0.49 earnings per share for the quarter, missing the consensus estimate of $0.50 by $0.01. The company earned $975 million during the quarter, compared to the consensus estimate of $968.54 million. Genesis Healthcare had a net margin of 17.83% and a trailing twelve-month return on equity of 155.48%.

Genesis Healthcare's Board of Directors initiated a stock buyback plan on Thursday, May 9th 2024, which permits the company to repurchase $3,000,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 23.1% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's management believes its stock is undervalued.

Top institutional shareholders of Genesis Healthcare include FMR LLC (5.90%), State Street Corp (4.24%), Pacer Advisors Inc. (2.76%) and Geode Capital Management LLC (2.19%). Insiders that own company stock include Ondrej Vlcek and Bryan Seuk Ko.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genesis Healthcare investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
10/30/2024
Ex-Dividend for 12/11 Dividend
11/18/2024
Dividend Payable
12/11/2024
Today
12/22/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Employees
2,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.33
High Stock Price Target
$37.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+12.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$836 million
Pretax Margin
23.69%

Debt

Sales & Book Value

Annual Sales
$2.80 billion
Cash Flow
$3.31 per share
Book Value
($0.16) per share

Miscellaneous

Free Float
618,038,000
Market Cap
$17.79 billion
Optionable
Optionable
Beta
0.84
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NYSE:GEN) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners